Inventor · disambiguated record
Eugene Zhukovsky
Also filed as: ZHUKOVSKY EUGENE · ZHUKOVSKY EUGENE A · ZHUKOVSKY EUGENE ALEXANDER
15 granted patents·16 pending applications·163 citations·filing 2003–2024
92Inventor score
Files withXENCOR INC10BIOMUNEX PHARMACEUTICALS7BERNETT MATTHEW J6AMPHIVENA THERAPEUTICS INC4AFFIMED GMBH3
Top patents by PatentIndex Score
31 records- 0196US8551485B2Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cellsBERNETT MATTHEW J·Filed 2009·Granted Oct 8, 2013·45 cites·27 claims
- 0296US8524867B2Optimized antibodies that target CD19BERNETT MATTHEW J·Filed 2007·Granted Sep 3, 2013·56 cites·32 claims
- 0392US11618788B2Optimized antibodies that target CD19XENCOR INC·Filed 2020·Granted Apr 4, 2023·2 cites·16 claims
- 0492US9212225B1Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Dec 15, 2015·17 cites·14 claims
- 0590US9803029B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2015·Granted Oct 31, 2017·11 cites·18 claims
- 0688US10626190B2Bispecific CD33 and CD3 binding proteinsAMPHIVENA THERAPEUTICS INC·Filed 2017·Granted Apr 21, 2020·3 cites·12 claims
- 0785US10066015B2CD3 binding domainsAFFIMED GMBH·Filed 2015·Granted Sep 4, 2018·10 cites·11 claims
- 0885US9803020B2Optimized antibodies that target CD19XENCOR INC·Filed 2013·Granted Oct 31, 2017·5 cites·24 claims
- 0985US2023340144A1Optimized antibodies that target cd19XENCOR INC·Filed 2023·Application pending·0 cites
- 1084US11560437B2Stable multispecific antibodiesBIOMUNEX PHARMACEUTICALS·Filed 2018·Granted Jan 24, 2023·4 cites·14 claims
- 1179US10626182B2Optimized antibodies that target CD19XENCOR INC·Filed 2017·Granted Apr 21, 2020·1 cites·27 claims
- 1276US11505616B2Binding molecules to CD38 and PD-L1BIOMUNEX PHARMACEUTICALS·Filed 2017·Granted Nov 22, 2022·1 cites·7 claims
- 1374US10273309B2Antibody binding sites specific for EGFRvIIIAFFIMED GMBH·Filed 2016·Granted Apr 30, 2019·2 cites·21 claims
- 1473US2024209118A1Polypeptide linker for preparing multispecific antibodiesBIOMUNEX PHARMACEUTICALS·Filed 2024·Application pending·0 cites
- 1565US2021024654A1Bispecific CD33 and CD3 Binding ProteinsAMPHIVENA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1663US2014112916A1Optimized Antibodies That Target CD19XENCOR INC·Filed 2013·Application pending·0 cites
- 1758US2012082664A1Optimized antibodies that target cd19BERNETT MATTHEW J·Filed 2011·Application pending·0 cites
- 1857US11958913B2Polypeptide linker for preparing multispecific antibodiesBIOMUNEX PHARMACEUTICALS·Filed 2018·Granted Apr 16, 2024·0 cites·12 claims
- 1957US2025282892A1Bispecific antibodies binding to her-3 and to either her-2 or egfrBIOMUNEX PHARMACEUTICALS·Filed 2023·Application pending·0 cites
- 2056US2022048994A1Trifunctional antigen-binding moleculeLITTLE MELVYN·Filed 2021·Application pending·0 cites
- 2155US7553930B2BAFF variants and methods thereofXENCOR INC·Filed 2004·Granted Jun 30, 2009·6 cites·11 claims
- 2254US2005003480A1April variants and methods thereofXENCOR INC·Filed 2004·Application pending·0 cites
- 2353US2004137581A1Interferon variants with improved propertiesXENCOR INC·Filed 2003·Application pending·0 cites
- 2453US2005054053A1Interferon variants with improved propertiesXENCOR INC·Filed 2004·Application pending·0 cites
- 2551US2005130892A1BAFF variants and methods thereofXENCOR INC·Filed 2004·Application pending·0 cites
- 2649US2008199471A1Optimized cd40 antibodies and methods of using the sameBERNETT MATTHEW J·Filed 2008·Application pending·0 cites
- 2749US2008254027A1Optimized CD5 antibodies and methods of using the sameBERNETT MATTHEW J·Filed 2007·Application pending·0 cites
- 2848US2008260731A1Optimized antibodies that target cd19BERNETT MATTHEW J·Filed 2007·Application pending·0 cites
- 2945US2023322952A1Multispecific antibodies that bind both mait and tumor cellsBIOMUNEX PHARMACEUTICALS·Filed 2021·Application pending·0 cites
- 3042US2017037128A1Trifunctional antigen-binding moleculeAFFIMED GMBH·Filed 2016·Application pending·0 cites
- 3136US12054550B2Bispecific antibodies targeting EGFR and HER2BIOMUNEX PHARMACEUTICALS·Filed 2017·Granted Aug 6, 2024·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Eugene Zhukovsky files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →